Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Tiber Laboratories
WARNING LETTER
•Tiber Laboratories

Tiber Laboratories – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Mr. Henson's firm, following a previous letter to (b)(4), regarding drug products manufactured by (b)(4) and distributed by Mr. Henson's firm, including (b)(4) and (b)(4). These products are deemed "new drugs" under section 201(p) of the Act because they are not generally recognized as safe and effective. The firm lacks FDA-approved applications for these new drugs, leading to violations of sections 301(a) and (d) and 505(a) of the Act for introducing unapproved new drugs into interstate commerce. Additionally, the products are misbranded under section 502(f)(1) of the Act because their labeling fails to bear adequate directions for use, as they are intended for conditions not amenable to self-diagnosis and treatment by laypersons (21 C.F.R. § 201.5). The products are also cited as adulterated under 21 U.S.C. § 351(a)(2)(B), further prohibiting their interstate commerce under 21 U.S.C. § 331(a). The FDA emphasizes that these violations are not exhaustive and may apply to all unapproved drug products marketed by the firm. The firm is required to promptly investigate and correct all identified violations and prevent recurrence. A written response detailing corrective actions, including supporting documentation and timelines, is due within fifteen working days. Failure to comply may result in legal action, such as seizure or injunction, and could impact future federal contracts.

Company
Tiber Laboratories
Product type
Drugs
Office
Atlanta District Office
Person
  • Anne P. Reid
View Company Profile

ID · f9baf500-92d9-42d6-b424-20950dc54846

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 U.S.C. 321(p)21 U.S.C. 331(d)21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 355(b)21 U.S.C. 355(j)21 CFR 201.5

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Tiber Laboratories
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.